{"id":"W2116773863","doi":"10.1093/rheumatology/kem294","title":"Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance","year":2007,"lang":"en","type":"letter","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Adalimumab; Etanercept; Ankylosing spondylitis; Infliximab; Nice; Spondylitis; Dermatology; Physical therapy; Intensive care medicine; Tumor necrosis factor alpha; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01148803,0.0009258064,0.00375455,0.002211335,0.001139667,0.00361909,0.002386955,0.02039716,0.007837491],"category_scores_gemma":[0.08636279,0.0007808146,0.003751375,0.002635207,0.001611085,0.00382525,0.001337367,0.01361173,0.005008414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006804302,"about_ca_system_score_gemma":0.009377969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01293854,"about_ca_topic_score_gemma":0.03194737,"domain_scores_codex":[0.9870515,0.005961041,0.002764779,0.0004143156,0.003303808,0.000504546],"domain_scores_gemma":[0.9449078,0.03605919,0.003102261,0.0009254825,0.01283614,0.00216921],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004308587,0.00003132611,0.0003638619,0.00156135,0.0001838448,0.0002717534,0.00004739231,0.0001247752,0.00009963633,0.002797776,0.9557621,0.03832525],"study_design_scores_gemma":[0.002416691,0.0001725859,0.002547278,0.009061057,0.0009365191,0.001647811,0.0001595256,0.0004326175,0.0001875195,0.01433958,0.9679986,0.0001001574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0008461984,0.12424,0.0004765178,0.8362715,0.02194113,0.000103172,0.001357606,0.00007557798,0.01468833],"genre_scores_gemma":[0.01403608,0.09047826,0.00589994,0.8385403,0.03825197,0.0004804948,0.001451208,0.0001139833,0.01074783],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02039716,"threshold_uncertainty_score":0.06075519,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06229210480695615,"score_gpt":0.3437443540948494,"score_spread":0.2814522492878933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}